Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Feb;17(1):52-7.
doi: 10.1111/j.1755-5949.2010.00228.x. Epub 2010 Dec 28.

Dopamine receptor homooligomers and heterooligomers in schizophrenia

Melissa L Perreault  1 , Brian F O'Dowd, Susan R George
Affiliations
Review

Dopamine receptor homooligomers and heterooligomers in schizophrenia

Melissa L Perreault et al. CNS Neurosci Ther. 2011 Feb.

Abstract

Over the past two decades the dopamine D2 receptor has been undoubtedly the most widely studied dopamine receptor for the therapeutic treatment of schizophrenia, as the majority of antipsychotics exhibit antagonism at this receptor. However, the cognitive symptoms of the disorder are mostly resistant to the majority of available antipsychotic treatments and, as a result, there is a critical need to develop novel therapies that ameliorate all symptoms. The recognition that dopamine receptors, such as all G protein-coupled receptors (GPCRs), exist as oligomeric complexes has provided new avenues for drug design in the search for novel therapies. Furthermore, that it is now known that dopamine receptors can form heteromers, such as the dopamine D1-D2 receptor heteromer, with pharmacology and function distinct from its constituent receptors, has significantly expanded the range of potential drug targets. The aim of this review is to discuss the therapeutic relevance of these dopamine receptor oligomers to schizophrenia and to address the potential value of dopamine receptor heteromers in the search for new therapeutic strategies.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Terrillon S, Bouvier M. Roles of G‐protein‐coupled receptor dimerization. EMBO Rep 2004;5:30–34. - PMC - PubMed
    1. Milligan G. G protein‐coupled receptor dimerization: Function and ligand pharmacology. Mol Pharmacol 2004;66:1–7. - PubMed
    1. George SR, O’Dowd BF, Lee SP. G‐protein‐coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov 2002;1:808–820. - PubMed
    1. Karpa KD, Lin R, Kabbani N, Levenson R. The dopamine D3 receptor interacts with itself and the truncated D3 splice variant d3nf: D3‐D3nf interaction causes mislocalization of D3 receptors. Mol Pharmacol 2000;58:677–683. - PubMed
    1. Hague C, Uberti MA, Chen Z, Hall RA, Minneman KP. Cell surface expression of alpha1D‐adrenergic receptors is controlled by heterodimerization with alpha1B‐adrenergic receptors. J Biol Chem 2004;279:15541–15549. - PubMed

Publication types

MeSH terms